在骨关节炎中使用大麻制药的证据:范围审查
Andrew T Y Xiao1, Tarek Turk2, Karanvir Deol3
1Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, 8-130 Clinical Science Building, 11350-83rd Ave, Edmonton, AB, T6G 2G3, Canada.
Clinical rheumatology
|June 9, 2024
概括
关于治疗骨关节炎的基于大麻的药物的证据是混合的. 虽然通常是安全的,并可能减少阿片类药物使用,但由于样本规模小,研究持续时间短,需要更多的研究.
科学领域:
- 风湿病学和疼痛管理
- 药理学和治疗学 药理学和治疗学
背景情况:
- 骨关节炎 (OA) 是一种常见的退行性关节疾病,导致疼痛和残疾.
- 基于大麻的药物 (CBM) 越来越多地被探索用于管理慢性疼痛疾病,如OA.
- 目前对OA的CBM的研究缺乏全面的综合,需要对当前证据进行审查.
研究的目的:
- 进行范围审查,绘制有关CBM治疗骨关节炎的有效性和安全性的现有证据.
- 确定与OA中CBM使用相关的研究类型,研究设计和报告结果.
主要方法:
- 在多个数据库 (MEDLINE,Embase,Cochrane Library,CINAHL,Scopus,Proquest) 进行了全面的文献搜索,截至2023年3月.
- 该审查遵循了阿克西和奥马利框架和PRISMA扩展范围审查指南.
- 包括的研究包括随机对照试验,横截面调查,案例研究和队列研究,共10篇文章.
主要成果:
- 关于CBM对OA疼痛的疗效的证据是混合的,60%的研究报告了统计学上显著的疼痛改善.
- 用更大的样本大小和更长的治疗时间进行的研究没有显示出明显的疼痛益处.
- 报告的不良反应通常是轻微的和不常见的;在一些研究中,CBM与减少阿片类药物使用有关.
结论:
- 目前关于OA的CBM的数据不足以支持临床建议.
- 一般轻微的副作用表明耐受性良好,但长期安全性需要进一步调查.
- 未来的研究应该专注于更大的样本大小和更长的治疗持续时间,以建立在OA管理中CBMs的强有力的证据.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
745
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
745
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
689
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
689
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
1.1K